Burzynski Research Institute Discloses Going Concern, Full Clinical Hold, and Critical Funding Dependency

summarizeZusammenfassung

This 10-Q filing reveals severe operational and financial challenges for Burzynski Research Institute. The explicit 'going concern' warning indicates substantial doubt about the company's ability to continue operations, primarily due to recurring losses, a working capital deficit, and negative operating cash flows. The company's survival is entirely dependent on funding from its President and majority shareholder, Dr. S.R. Burzynski, through his medical practice. Furthermore, all clinical trials for its Antineoplaston drugs remain under a full FDA clinical hold, preventing new patient enrollment and severely hindering its core research and development activities. These factors collectively present an extremely high risk to investors, highlighting the company's precarious financial position and uncertain future.

check_boxSchlusselereignisse

• Going Concern Warning Issued

  The company explicitly states substantial doubt about its ability to continue as a going concern due to recurring losses, a working capital deficit, and negative operating cash flows.

• Full FDA Clinical Hold Continues

  All investigational new drug (IND) applications for Antineoplaston drugs remain under a full clinical hold by the FDA, preventing the enrollment of new patients into any clinical trials.

• Critical Economic Dependency

  The company is entirely dependent on financial contributions from its President and majority shareholder, Dr. S.R. Burzynski, through his medical practice for its capital and operational needs.

• Limited Cash and Worsening Working Capital

  Cash and cash equivalents stood at a minimal $2,165 as of November 30, 2025, with a working capital deficit worsening to $(67,343) from $(41,637) at February 28, 2025.

auto_awesomeAnalyse

This 10-Q filing reveals severe operational and financial challenges for Burzynski Research Institute. The explicit 'going concern' warning indicates substantial doubt about the company's ability to continue operations, primarily due to recurring losses, a working capital deficit, and negative operating cash flows. The company's survival is entirely dependent on funding from its President and majority shareholder, Dr. S.R. Burzynski, through his medical practice. Furthermore, all clinical trials for its Antineoplaston drugs remain under a full FDA clinical hold, preventing new patient enrollment and severely hindering its core research and development activities. These factors collectively present an extremely high risk to investors, highlighting the company's precarious financial position and uncertain future.